«

»

ICARE Newsletter Summer 2020

Treatment Advances Among Those with Neurofibromatosis Type 1

image_print

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below:

Neurofibromatosis Type 1 (NF1): 

The FDA granted selumetinib (a MEK inhibitor) breakthrough therapy designation for treatment of inoperable plexiform neurofibromas.

Permanent link to this article: https://inheritedcancer.net/8nls2020/